Welcome, everyone, to the webcast for Ascelia Pharma Q4 report for 2025.
On this call, we will be making forward-looking statements. On today's call, we will start with an overview of Ascelia Pharma's recent key events and then head into the portfolio update before moving on to financials and priorities ahead. After the presentation, we will open up for questions.
As usual, I'm Magnus Corfitzen, CEO of Ascelia Pharma, and with me today I have Julie Waras Brogren, Deputy CEO, Andreas Norlin, Chief Scientific Officer, and Anton Hansson, CFO.
I'm pleased to welcome Anton to his first quarterly call as Chief Financial Officer.
This will also be the last quarterly call with Julie, as she will be moving on to new opportunities, as we announced a few weeks ago. At Ascelia Pharma, we identify, develop, and commercialize novel drugs that address unmet medical needs across rare cancer conditions. We're based in Malmö, Sweden, and are listed on Nasdaq Stockholm.
We have two drugs in our pipeline. Orviglance is a diagnostic drug that is now under FDA review with the PDUFA date of July 3rd this year. We will spend the majority of this call talking about Orviglance. Oncoral is a patented tablet formulation of Irinotecan, with encouraging results in Phase 1 and potential to treat a range of solid tumors.
We are very excited about Orviglance, and here's why.
Orviglance is addressing a well-defined unmet medical need for a subgroup of people living with cancer.
This translates into an $800 million addressable global market opportunity, and Orviglance is a first-in-class product to target this market and has Orphan Drug Designation from the FDA. We have commercial-scale manufacturing in place, and we have strong data from nine different clinical studies, including very compelling Phase 3 data. As mentioned, the Orviglance New Drug Application has been submitted to the FDA, and the review process is ongoing.
The key milestone in the fourth quarter of 2025 was the FDA acceptance of the Orviglance NDA. In mid-November, the Day 74 letter was received. This means that the FDA has reviewed the NDA file and decided it has the quality that warrants a full review. The FDA has also set a PDUFA date of July 3rd this year.
This is the date when they expect to have made a decision on approval.
In Q4, we submitted a new patent application for manufacturing of Orviglance, which may extend the exclusivity period for Orviglance. In November, we announced the appointment of Anton Hansson as our new Chief Financial Officer, and he started a few weeks ago. Anton has a background in corporate finance and most recently worked with KPMG. I'm very happy to have him join our team. The long-term incentive program of 2022 vested, and 53,000 shares were awarded in November to employees who had purchased and held the shares throughout the three-year period.
Also in Q4, the nomination committee was appointed by the largest shareholders in Ascelia Pharma.
After the close of the quarter earlier this January, we announced that Julie will be leaving Ascelia Pharma, and I would like to thank her for her contributions to Ascelia throughout the years and wish her best of luck in her new role. There are two major value-creating milestones for Orviglance, and we are on track to meet both of them. The first objective is the FDA approval of Orviglance, and the key milestone of this is the submission we made in September last year. In mid-November, the FDA set a date, which is July 3rd this year. And this is, as mentioned, the date when they expect to make a decision on approval, and activities for the NDA review, including the interactions with the FDA, are progressing well, and we continue to be on track for approval.
The second objective is to progress Orviglance for commercialization. This is a two-pronged approach. One is to continue our work to advance launch readiness by ensuring manufacturing and supply chain is as ready for launch as possible, as well as working with medical experts and including key opinion leaders, payers and other key stakeholders. The other track that we are also working on is to make a deal with a partner who will drive the commercialization.
Julie will follow up on our progress there. I'm very happy with the progress we are making on these important milestones, and I'm optimistic for a very strong 2026. For Ascelia Pharma. We will start the portfolio section of our presentation with Orviglance. And I'll hand over to Julie.